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Nature's editorial, dated 10 December 2015, made several criticisms of the new Japanese conditional and
time-limited marketing authorization system for regenerative medical products. We believe these
comments were based on a misunderstanding of the purpose of the regulations, which are patient-
oriented, offering patients access to promising regenerative medicines in a timely manner at reason-
able expense while also ensuring the efﬁcacy and safety of the medicines. The new regulatory system
represents an attempt by Japan to accommodate unmet medical needs, particularly for life-threatening
diseases, and is in line with current global regulatory trends to enable early patient access to new
therapies.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Main text
Nature's editorial of 10 December 2015 [1] suggested that the
new Japanese conditional and time-limited marketing authoriza-
tion system for regenerative medical products represents a subsidy
of commercial clinical trials, and would result in proliferation of
unsuccessful treatments. We appreciate Nature's interest, but think
these comments are based on amisunderstanding of the purpose of
the Japanese system, which is patient-oriented. A key aim of the
conditional and time-limited marketing authorization system is to
open up new treatment possibilities for patients who otherwise
have very limited or no treatment options. In other words, clinical
trials of new regenerative medicines can be regarded as limited
treatment opportunities for limited patient subpopulations. We
have conventionally conducted review processes for orphan drugs
from such a point of view. The new legal regulatory system for
regenerative medical products is based on the same philosophy,iation; LVEF, left ventricular
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ative Medicine. Production and hotaking account of the fact that evaluation of such products is often
difﬁcult due to heterogeneity when live cells are used as raw ma-
terials. The resulting non-uniform character will make conﬁrma-
tion of their effectiveness and quality characterization relatively
difﬁcult, compared with pharmaceuticals and medical devices.
An example of a product covered by the new regulations is the
cultured autologous myoblast product, HeartSheet. This product
has been given conditional and time-limited marketing authori-
zation for patients who have heart disease with severe left ven-
tricular dysfunction (LVEF) due to ischemic heart disease. As
required for a conditional and time-limited marketing authoriza-
tion, HeartSheet demonstrated its likely efﬁcacy through the
exploratory study (phase II trial (n ¼ 7), using efﬁcacy endpoints:
LVEF, etc.). It was additionally required a conﬁrmation of product
efﬁcacy and further safety measures, including limiting medical
institutions with capable facilities and experts for use. For full
approval, following its conditional and time-limited approval
within 5 years, the postmarketing study protocol has been
designed to compare survival rates between patients with and
without HeartSheet [2].
Patients who are eligible to receive this treatment must satisfy
the criteria of the New York Heart Association (NYHA) III or IV, and
show LVEF < 35% despite having received all available treatments,
including invasive therapy such as valve replacement. For such
patients, who have heart disease with severe dysfunction, are non-sting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
D. Sato et al. / Regenerative Therapy 4 (2016) 103e104104responsive to standard drug therapy, and have a poor prognosis [3],
heart transplantation is the only deﬁnitive treatment option.
However, there is an extreme shortage of donors for heart trans-
plantation in Japan. Therefore, myoblast sheets provide a new
treatment option, with likely clinical beneﬁt for patients with se-
vere dysfunction of the left ventricle caused by ischemic heart
disease, who cannot receive a ventricular assist device or cardiac
transplantation.
In this sense, the conditional and time-limited authorization of
HeartSheet is purely patient-oriented, its aim being to make
potentially promising treatment available in a timely manner to
patients without other options, not to provide proﬁt to biotech-
nology enterprises. It should be noted that a large part of the cost of
such treatments is met by the Japanese health insurance system,
not by patients themselves, as long as the treatment is considered
reasonably likely to offer clinical beneﬁt. It is provided under the
“High-cost medical care beneﬁt” scheme, which places a maximum
limit on patients' monthly payment, depending on their income.
For example, a patient who is under 70 years old, whose annual
income is 30,000e62,600 USD (3.7e7.7 million JPY), and whose
medical expenses are 122,000 USD (15 million yen)/month, would
pay only 1900 USD (230,000 JPY)/month (1 USD ¼ 123 JPY on 9
December 2015).
Japan is one of the founding members of the International
Council for Harmonization of Technical Requirements for Phar-
maceuticals for Human Use (ICH), and has a sophisticated product
review system to ensure product safety and efﬁcacy. As pointed out
by Konomi et al. [4], to obtain conditional and time-limited
approval, it is required that exploratory clinical trials predict a
reasonable likelihood of clinical beneﬁt (for example, by using a
surrogate endpoint). This approach is consistent with the US Food
and Drug Administration's (FDA's) accelerated approval scheme for
serious or life-threatening illnesses (www.fda.gov). The accelerated
approval allows for approval if the drug product has an effect on a
surrogate endpoint that is reasonably likely to predict clinical
beneﬁt or on the basis of an effect on a clinical endpoint other thansurvival or irreversible morbidity, but is subject to the requirement
that the applicant study the drug further, to verify and describe its
clinical beneﬁt. Moreover, the European Agency (www.ema.europa.
eu/ema/) is also putting forward an adaptive approach to condi-
tional approval for early access, which is prospectively planned, and
where uncertainty is reduced through collection of post-approval
data on the medicine's use in patients [5]. It requires conﬁrming
the beneﬁt-risk balance of a product, following a conditional
approval based on early data (using surrogate endpoints) consid-
ered predictive of important clinical outcomes. The approval is
granted in stages, beginning with a restricted patient population.
In conclusion, we would like to emphasize that the new Japa-
nese conditional and time-limited marketing authorization system
for regenerative medical products represents an attempt to deliver
potentially beneﬁcial treatments in a timely manner to patients
who have few or no other options, while ensuring efﬁcacy and
safety. This approach is well aligned with current global regulatory
trends to enable early patient access to new therapies, particularly
for life-threatening diseases.Conﬂict of interest
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